Incidence, mortality and survival trends of penile cancer in Lithuania 1998-2017.
cancer
epidemiology
incidence
mortality
penile
survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
01
2023
accepted:
24
04
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
The aim of this study was to analyse trends in penile cancer incidence, mortality, and relative survival in Lithuania during the period of 1998-2017. The study was based on all cases of penile cancer reported to the Lithuanian Cancer Registry between 1998 and 2017. Age-specific rates standardized rates were calculated, using the direct method (World standard population). The Joinpoint regression model was used to provide estimated average annual percentage change (AAPC). One-year and five-year relative survival estimates were calculated using period analysis. Relative survival was calculated as the ratio of the observed survival of cancer patients and the expected survival of the underlying general population. During the study period, the age-standardized incidence rate of penile cancer varied between 0.72 and 1.64 per 100 000, with AAPC 0.9% (95% CI -0.8-2.7). The mortality rate of penile cancer in Lithuania during this period varied from 0.18 to 0.69 per 100 000, with AAPC of -2.6% (95% CI -5.3-0.3). Relative one-year survival of patients, diagnosed with penile cancer improved over the time from 75.84% in period 1998-2001 to 89.33% in period 2014-2017. Relative five-year survival rate of patients, diagnosed with penile cancer changed from 55.44% in period 1998-2001 to 72.90% in period 2014-2017. The incidence rates of penile cancer showed an increasing trend, while mortality rates were decreasing in Lithuania during 1998-2017. One-year and five-year relative survival increased, however, it does not reach the highest scores of Northern European countries.
Sections du résumé
Background and objectives
UNASSIGNED
The aim of this study was to analyse trends in penile cancer incidence, mortality, and relative survival in Lithuania during the period of 1998-2017.
Materials and methods
UNASSIGNED
The study was based on all cases of penile cancer reported to the Lithuanian Cancer Registry between 1998 and 2017. Age-specific rates standardized rates were calculated, using the direct method (World standard population). The Joinpoint regression model was used to provide estimated average annual percentage change (AAPC). One-year and five-year relative survival estimates were calculated using period analysis. Relative survival was calculated as the ratio of the observed survival of cancer patients and the expected survival of the underlying general population.
Results
UNASSIGNED
During the study period, the age-standardized incidence rate of penile cancer varied between 0.72 and 1.64 per 100 000, with AAPC 0.9% (95% CI -0.8-2.7). The mortality rate of penile cancer in Lithuania during this period varied from 0.18 to 0.69 per 100 000, with AAPC of -2.6% (95% CI -5.3-0.3). Relative one-year survival of patients, diagnosed with penile cancer improved over the time from 75.84% in period 1998-2001 to 89.33% in period 2014-2017. Relative five-year survival rate of patients, diagnosed with penile cancer changed from 55.44% in period 1998-2001 to 72.90% in period 2014-2017.
Conclusions
UNASSIGNED
The incidence rates of penile cancer showed an increasing trend, while mortality rates were decreasing in Lithuania during 1998-2017. One-year and five-year relative survival increased, however, it does not reach the highest scores of Northern European countries.
Identifiants
pubmed: 37213282
doi: 10.3389/fonc.2023.1124101
pmc: PMC10196467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1124101Informations de copyright
Copyright © 2023 Drevinskaite, Patasius, Kincius, Jonušas, Ladukas, Jievaltas, Kairevice and Smailyte.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Urol. 1995 Mar;75(3):375-7
pubmed: 7735804
Popul Health Metr. 2016 Mar 01;14:4
pubmed: 26933388
JAMA. 2011 Oct 5;306(13):1479-80
pubmed: 21972310
Front Oncol. 2022 Jun 17;12:891623
pubmed: 35785206
Lancet Oncol. 2019 Jan;20(1):145-158
pubmed: 30573285
Lancet Oncol. 2004 Apr;5(4):240-7
pubmed: 15050955
Urology. 2010 Aug;76(2 Suppl 1):S2-6
pubmed: 20691882
Eur J Cancer. 2015 Oct;51(15):2206-2216
pubmed: 26421823
Br J Urol. 1993 Nov;72(5 Pt 2):817-9
pubmed: 8281416
Clin Vaccine Immunol. 2012 Feb;19(2):261-7
pubmed: 22155768
Curr Opin Urol. 2019 Mar;29(2):145-149
pubmed: 30562185
Eur J Surg Oncol. 2019 Jan;45(1):1-2
pubmed: 30041942
N Engl J Med. 2011 Feb 3;364(5):401-11
pubmed: 21288094
J Urol. 2014 Jan;191(1):68-73
pubmed: 23917166
CA Cancer J Clin. 2016 Nov 12;66(6):481-495
pubmed: 27314890
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
JMIR Public Health Surveill. 2022 Jul 6;8(7):e34874
pubmed: 35793140
Front Public Health. 2023 Feb 21;11:1067299
pubmed: 36895694
Nat Rev Dis Primers. 2021 Feb 11;7(1):11
pubmed: 33574340
Med Microbiol Immunol. 2004 Feb;193(1):35-44
pubmed: 12838415
Science. 1947 Apr 11;105(2728):391-2
pubmed: 17841584
Transl Androl Urol. 2017 Oct;6(5):791-802
pubmed: 29184775
Vaccine. 2018 May 3;36(19):2529-2544
pubmed: 29625764
Int J Cancer. 2018 Apr 15;142(8):1586-1593
pubmed: 29205336
Eur Urol. 2022 Nov;82(5):458-468
pubmed: 35853783
Transl Androl Urol. 2017 Oct;6(5):874-878
pubmed: 29184785
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
J Am Acad Dermatol. 2002 Jul;47(1):33-9
pubmed: 12077578
Rev Panam Salud Publica. 2017 Nov 30;41:e117
pubmed: 31384255
Rev Med Virol. 2009 Mar;19(2):97-113
pubmed: 19156753
Int J Cancer. 2015 Nov 1;137(9):2060-71
pubmed: 26135522
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915976
Cancer Causes Control. 2012 Feb;23(2):273-80
pubmed: 22101453